What Has Been the Growth Trajectory for the Polyclonal Antibodies Market in Recent Years?
The polyclonal antibodies market has seen considerable growth due to a variety of factors.
•In recent periods, the polyclonal antibodies market size has experienced substantial growth. This sector, which was valued at $1.41 billion in 2024, is projected to rise to $1.5 billion in 2025, with a compound annual growth rate (CAGR) of 6.0%.
Factors such as the pressing requirements in biomedical research, the surge in diagnostic applications, a rise in cases of chronic diseases and a diversity of applications have contributed to the growth in the previous period.
How Does the Forecast Look for the Polyclonal Antibodies Market?
The polyclonal antibodies market is expected to maintain its strong growth trajectory in upcoming years.
• Expectations for the polyclonal antibodies market project a vigorous expansion in the forthcoming years, estimated to reach $1.97 billion in 2029, experiencing a compound annual growth rate (CAGR) of 7.1%.
Factors contributing to this projected growth during the forecasted period include the progression of diagnostic technologies, advancements in therapeutics, the prevalence of infectious diseases, the increase in funding for research, and the occurrence of partnerships and collaborations. Notable trends for this period include progress in antibody engineering, an enhanced role in cancer immunotherapy, the emergence of biosimilar polyclonal antibodies, applications in treating neurological disorders, as well as regulatory advancements and compliance.
What Main Forces Are Fueling Expansion In The Polyclonal Antibodies Market?
The rise in cancer incidence is anticipated to spur the expansion of the polyclonal antibodies market. These antibodies are employed in cancer management and research for the detection of biomarkers, immunohistochemistry, targeted therapy, and immunotherapy, thereby enhancing diagnosis, treatment, and patient results associated with cancer. The surge in the number of people diagnosed with cancer is boosting the polyclonal antibodies market growth. For example, Cancer Australia, a cancer control organization established in Australia, predicted in September 2022 that 2,572 new stomach cancer cases (1,661 men and 911 women) will be identified in Australia during 2022. An individual has a 1 in 114 (or 0.87%) risk of developing stomach cancer by 85 years of age in 2022, (1 in 1.1 or 87% for males, and 1 in 167 or 0.60% for females). As a result, the escalating occurrence of cancer is a significant factor propelling the progress of the polyclonal antibodies market.
What Are The Primary Segments In The Global Polyclonal Antibodies Market?
The polyclonal antibodies market covered in this report is segmented –
1) By Product Type: Primary Antibody, Secondary Antibody
2) By Source: Rabbits, Goats, Sheep, Other Sources
3) By Application: Research, Diagnostics, Therapy
4) By End-User: Academic and Research Center , Pharmaceutical and Biotechnology Companies, Diagnostic Centers , Hospitals
Subsegments:
1) By Primary Antibody: Immunoglobulin G (IgG), Immunoglobulin M (IgM), Immunoglobulin A (IgA), Immunoglobulin E (IgE)
2) By Secondary Antibody: Anti-Mouse IgG, Anti-Rabbit IgG, Anti-Goat IgG, Other Secondary Antibodies
Pre-Book The Polyclonal Antibodies Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
Which Key Trends Are Driving Changes In The Polyclonal Antibodies Market?
The primary trends emerging in the polyclonal antibodies market are connected to research and development. Lead players in the polyclonal antibodies industry are honing their observation skills and maintain their market standing through continuous research and development efforts. One such instance is from July 2022 when a research article titled ‘GMP manufacturing and IND-enabling studies of a recombinant hyperimmune globulin targeting SARS-CoV-2,’ was published by GigaGen Inc., a US-based bio-tech firm, in the renowned international journal, Pathogens. The article first introduces the recombinant polyclonal product that targets SARS-CoV-2, dubbed GIGA-2050, and delves into GMP (good manufacturing practice) production and IND (Investigational Novel Drug)-enabling research related to this new category of drugs – recombinant polyclonal antibodies. GIGA-2050 comprises more than 12,000 antibodies obtained from a single master cell bank (MCB). Earlier, production processes for significantly smaller recombinant antibody combinations typically included creating separate MCBs for each monoclonal antibody and amalgamating the MCBs prior to production.
Who Are the Key Players in the Polyclonal Antibodies Market?
Major companies operating in the polyclonal antibodies market include:
• Abcam plc
• GenScript Biotech Corporation
• Merck KGaA
• Thermo Fisher Scientific Inc.
• Becton Dickinson and Company
• BioLegend Inc.
• Bio-Rad Laboratories Inc.
• Cell Signaling Technology Inc.
• F. Hoffmann-La Roche Ltd.
• PerkinElmer Inc.
• Creative Diagnostics
• Agilent Technologies
• Analytik Jena GmbH
• Atlas Antibodies
• Danaher Corporation
• DC Biosciences Ltd.
• Illumia Inc.
• ImmonoPresice Antibodies Ltd
• Fujirebio
• Omega BioTek Inc.
• Dovetail Genomics LLC
• Abnova Corporation
• Santa Cruz Biotechnology Inc.
• Enzo Life Sciences Inc.
• Rockland Immunochemicals Inc.
• IGY Life Sciences
• Genway Biotech
• Good Biotech
• Gallus Immunotech Inc.
• BioGenes GmbH
• Capralogics Inc.
• Bio X Cell
What Is The Most Dominant Region In The Polyclonal Antibodies Market?
North America was the largest region in the polyclonal antibodies market in 2024. Asia-Pacific is expected to be the fastest-growing region in the global polyclonal antibodies market size forecast period. The regions covered in the polyclonal antibodies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
